紫杉醇联合希罗达治疗进展期胃癌

Paclitaxel plus Xeloda in the treatment of advanced gastric cancer

目的:评价紫杉醇联合希罗达治疗晚期胃癌的疗效及毒副反应。方法:22例进展期胃癌患者,应用紫杉醇80mg/m2,d1,8,希罗达1000mg/m2,bid,d1-14,口服,每3周重复。结果:有效率(CR+PR)59%(13/22),疾病进展时间6.5月,中位生存期11.4月,1年生存率43.5%,生活质量改善75%。主要不良反应为骨髓抑制,Ⅲ/Ⅳ度骨髓抑制27%,手足综合症47%,胃肠道反应42%,多为Ⅰ/Ⅱ度。结论:紫杉醇联合希罗达治疗进展期胃癌疗效好,不良反应可耐受。

Objective：To evaluate the efficacy and side - effect of paclitaxel plus Xeloda in patients with gastric cancer. Methods： Twenty two patients received intravenous paclitaxel 80mg/m^2/d （day 1,8 ） with oral Xeloda 1000mg/m^2 twice daily （day 1 - 14 ） ,repeated every 3 weeks. Results：All 22 patients were evaluated for responds. The overall clinical response rate was 59% （13/22）. The time to progression was 6.5 months. Median Survival was 11.4 months. One year survival rate was 43.5% , and 75% cases acquired improved life quality. The major toxicity included Ⅲ- Ⅳ degree bone marrow inhibition （ 27% ） , hand - food - syndrome （ 47% ）, nausea and vomiting （42%）. The charity hand - food - syndrome and hand - food - syndrome were Ⅰ - Ⅱ degree toxicity. Conclusion： The combination of paclitaxel and Xeloda is an effective therapy for the patients with advanced gastric cancer, toxicity is acceptable.